

WEST Search History

DATE: Friday, November 15, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB; PLUR=YES; OP=OR</i>			
L1	fendly.in.	12	L1

END OF SEARCH HISTORY

result in loss of user privileges and other penalties.
***** STN Columbus *****

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREIGN no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
STN Operating Hours Plus Help Desk Availability
NEWS HOURS General Internet Information
NEWS INTER Welcome Banner and News Items
NEWS LOGIN Direct Dial and Telecommunication Network Access to STN
NEWS PHONE CAS World Wide Web Site (General information)
NEWS WWW

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may

FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002

=> file medline, cancerlit, biosis, confsci, caplus, embase, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 10:53:32 ON 05 NOV 2002

FILE 'CANCERLIT' ENTERED AT 10:53:32 ON 05 NOV 2002

FILE 'BIOSIS' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CONFSCI' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 10:53:32 ON 05 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:53:32 ON 05 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:53:32 ON 05 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

<-----User Break----->
<-----User Break----->
u

SEARCH ENDED BY USER

=> s her2 or erb2 or cerbb2 or pl85
L1 9309 HER2 OR ERB2 OR CERBB2 OR P185

=> s l1 and antibody?
L2 3941 L1 AND ANTIBOD?

=> s l2 and chemotherapeutic?
L3 503 L2 AND CHEMOTHERAPEUTIC?

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 418 DUP REM L3 (85 DUPLICATES REMOVED)

=> s l4 not py=>1996
'1996' NOT A VALID FIELD CODE
6 FILES SEARCHED...
L5 5 L4 NOT PY=>1996

=> d 1-5

L5 ANSWER 1 OF 5 MEDLINE
AN 91365853 MEDLINE
DN 91365853 PubMed ID: 1679763
TI Monoclonal antibody therapy of human cancer: taking the
HER2 protooncogene to the clinic.

AU Shepard H M; Lewis G D; Sarup J C; Fendly B M; Maneval D; Mordenti J;
 Figari I; Kotts C E; Palladino M A Jr; Ullrich A; +
 CS Department of Developmental Biology, Genentech, Inc., South San Francisco,
 California 94080.
 SO JOURNAL OF CLINICAL IMMUNOLOGY, (1991 May) 11 (3) 117-27. Ref: 35
 Journal code: 8102137. ISSN: 0271-9142.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 DT General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 199110
 ED Entered STN: 19911103
 Last Updated on STN: 20000303
 Entered Medline: 19911011
 L5 ANSWER 2 OF 5 CANCERLIT
 AN 95611685 CANCERLIT
 DN 95611685
 TI Monoclonal antibodies directed against growth factor receptors
 enhance the efficacy of chemotherapeutic agents (Meeting
 abstract).
 AU Baselga J; Fan Z; Norton L; Mendelsohn J
 CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
 SO Ann Oncol. (1994) 5 (Suppl 5) A010.
 ISSN: 0923-7534.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 199509
 ED Entered STN: 19950906
 Last Updated on STN: 19950906
 L5 ANSWER 3 OF 5 USPATFULL
 AN 95105868 USPATFULL
 TI Cell signaling inhibitors
 IN Michnick, John, Seattle, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5470878 19951128
 AI US 1993-164081 19931208 (8)
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned
 DT Utility
 FS Granted
 INCL INCLM: 514/558.000
 INCL INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;
 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
 NCLM: 514/558.000
 NCLS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;
 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000;
 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
 (6)
 ICM: A61K031-20
 ICS: C07C233-00

EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198;
 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552;
 514/523; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 4 OF 5 USPATFULL
 AN 9547701 USPATFULL
 TI Polymeric carriers for non-covalent drug conjugation
 IN Gustavson, Linda M., 19809 - 31st St., NE., Seattle, WA, United States
 98155
 Anderson, David C., 200 Lassen Dr., San Bruno, CA, United States 94066
 Morgan, Jr., Alton C., 803 Driftwood Pl., Edmonds, WA, United States
 98020
 PI US 5420105 19950530
 AI US 1993-95515 19930726 (8)
 RLI Continuation-in-part of Ser. No. US 1988-248456, filed on 23 Sep 1988,
 now patented, Pat. No. US 5252713
 DT Utility
 FS Granted
 INCL INCLM: 514/032.000
 INCL INCLS: 424/178.100; 514/008.000; 514/387.000; 530/350.000; 530/363.000;
 530/357.000; 530/370.000; 530/392.000; 530/409.000; 548/304.100
 NCLM: 514/032.000
 NCLS: 424/178.100; 514/008.000; 514/387.000; 530/350.000; 530/363.000;
 530/357.000; 530/370.000; 530/392.000; 530/409.000; 548/304.100
 (6)
 ICM: A61K031-415
 ICS: A61K047-42; A61K047-48
 EXF 514/2; 514/8; 514/387; 435/188; 530/350; 530/351; 530/362; 530/363;
 530/387.3; 530/392; 530/399; 530/391.7; 530/391.9; 530/402; 530/367;
 530/370; 530/409; 530/825; 424/85.91; 424/178.1; 548/303.7; 548/304.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 5 OF 5 USPATFULL
 AN 9415504 USPATFULL
 TI Method for prognosticating response to cancer therapy
 IN Bacus, Sarah S., Hinsdale, IL, United States
 PA Becton, Dickinson and Company, Franklin Lakes, NJ, United States (U.S.
 corporation)
 PI US 5288477 19940222
 AI US 1993-32529 19930315 (8)
 RLI Continuation of Ser. No. US 1991-767041, filed on 27 Sep 1991, now
 abandoned
 DT Utility
 FS Granted
 INCL INCLM: 424/002.000
 INCL INCLS: 424/035.500; 435/007.100; 436/501.000
 NCLM: 435/007.230
 NCLS: 424/035.500; 435/007.100; 435/029.000; 436/501.000
 (5)
 ICM: G01N001-00
 ICS: G01N033-48; G01N033-566; C12Q001-68
 EXF 424/2; 424/85.8; 435/7.1; 436/501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 => d his
 (FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002)
 FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
 ENTERED AT 10:53:32 ON 05 NOV 2002
 L1 9309 S HER2 OR ERB2 OR CERBB2 OR P185

L2 3941 S L1 AND ANTIBODY?
 L3 503 S L2 AND CHEMOTHERAPEUTIC?
 L4 418 DUP REM L3 (85 DUPLICATES REMOVED)
 L5 5 S L4 NOT PY=>1996

 => s l1 and antibody
 L6 3941 L1 AND ANTIBODY

 => s l6 and chemo?
 L7 1252 L6 AND CHEMO?

 => s l7 and cancer
 L8 1178 L7 AND CANCER

 => s l8 and colorectal
 L9 206 L8 AND COLORECTAL

 => dup rem l9
 PROCESSING COMPLETED FOR L9
 L10 204 DUP REM L9 (2 DUPLICATES REMOVED)

 '1996' NOT A VALID FIELD CODE
 6 FILES SEARCHED...
 L11 0 L10 NOT PY=> 1996

 => d l10 1-50

 L10 ANSWER 1 OF 204 USPATFULL
 AN 2002:280327 USPATFULL
 TI Compositions and methods for the diagnosis and treatment of tumor
 IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Godowski, Paul J., Burlingame, CA, UNITED STATES
 Gurney, Austin, Belmont, CA, UNITED STATES
 Polakis, Paul, Burlingame, CA, UNITED STATES
 Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 Wu, Thomas D., San Francisco, CA, UNITED STATES
 Zhang, Zemin, Foster City, CA, UNITED STATES
 GEMENTECH, INC. (U.S. corporation)
 US 2002161199 A1 20021031
 US 2001-938418 A1 20010823 (9)
 Continuation of Ser. No. WO 1999-US05028, filed on 8 Mar 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US12252, filed on 2 Jun 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US20111, filed on 1 Sep 1999, UNKNOWN
 Continuation of Ser. No. WO 1999-US28565, filed on 2 Dec 1999, UNKNOWN
 Continuation of Ser. No. WO 2000-US4342, filed on 18 Feb 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US4341, filed on 18 Feb 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US5841, filed on 2 Mar 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US8439, filed on 30 Mar 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US14042, filed on 22 May 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US23328, filed on 24 Aug 2000, UNKNOWN
 Continuation of Ser. No. WO 2000-US32678, filed on 1 Dec 2000, UNKNOWN
 Continuation of Ser. No. WO 2001-US6520, filed on 28 Feb 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US17800, filed on 1 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US19692, filed on 20 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US21066, filed on 29 Jun 2001, UNKNOWN
 Continuation of Ser. No. WO 2001-US21735, filed on 9 Jul 2001, UNKNOWN
 US 1998-81071P 19980408 (60)
 US 1998-85697P 19980515 (60)
 US 1998-97022P 19980818 (60)
 US 1998-101922P 19980924 (60)
 US 1998-103679P 19981008 (60)
 Utility
 PRAI

 L10 ANSWER 2 OF 264 USPATFULL
 AN 2002:280841 USPATFULL
 TI Pyroole substituted 2-indolinone protein kinase inhibitors
 IN Tang, Peng Cho, Moraga, CA, UNITED STATES
 Miller, Todd A., Bend, OR, UNITED STATES
 Li, Xiaoyuan, Los Altos, CA, UNITED STATES
 Sun, Li, Foster City, CA, UNITED STATES
 Wei, Chung Chen, Foster City, CA, UNITED STATES
 Shirazian, Shahrzad, Corte Madera, CA, UNITED STATES
 Liang, Congxin, Sunnyvale, CA, UNITED STATES
 Vojtkovsky, Tomas, San Francisco, CA, UNITED STATES
 Nematala, Asaad S., Concord, CA, UNITED STATES
 Hawley, Michael, Kalamazoo, MI, UNITED STATES
 US 2002156292 A1 20021024
 PI US 2001-783264 A1 20010215 (9)
 PRAI US 2000-182710P 20000215 (60)
 US 2000-216422P 20000706 (60)
 US 2000-243532P 20001027 (60)
 Utility
 DT
 FS APPLICATION
 LN.CNT 7280
 INCL INCLM: 548/487.000
 NCL NCLM: 548/487.000
 IC [7]
 ICM: C07D043-02

 L10 ANSWER 3 OF 204 USPATFULL
 AN 2002:280802 USPATFULL
 TI Novel Stra6 polypeptides
 IN Pennica, Diane, Burlingame, CA, UNITED STATES
 Smith, Victoria, Burlingame, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 US 2002156252 A1 20021024
 PI US 2001-759056 A1 20010111 (9)
 PRAI US 2000-228914P 20000829 (60)
 US 2000-197039P 20000414 (60)
 US 2000-175849P 20000113 (60)
 Utility
 DT
 FS APPLICATION
 LN.CNT 6615
 INCL INCLM: 536/023.100
 NCL NCLM: 536/023.100
 IC [7]
 ICM: C07H021-02
 ICS: C07H021-04

 L10 ANSWER 4 OF 204 USPATFULL
 AN 2002:280599 USPATFULL
 TI Use of Ext genes for the treatment of cancer and other diseases
 IN Tufaro, Frank, Vancouver, CANADA
 McCormick, M. Craig, Vancouver, CANADA
 University of British Columbia, Vancouver, CANADA (U.S. corporation)
 US 2002156044 A1 20021024
 PI US 2002-106092 A1 20020325 (10)
 DT

RLI Continuation of Ser. No. US 1998-60940, filed on 15 Apr 1998, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 1597
 INCL INCLM: 514/044.000
 INCLS: 435/456.000; 514/056.000
 NCL NCLM: 514/044.000
 NCLS: 435/456.000; 514/056.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K031-727; C12N015-86; C12N015-861; C12N015-867

L10 ANSWER 5 OF 204 USPATFULL
 AN 2002:280588 USPATFULL
 TI Immunostimulatory nucleic acids and cancer medicament
 IN Bratzler, Robert L., Concord, MA, UNITED STATES
 PI Petersen, Deanna M., Newton, MA, UNITED STATES
 AI US 2002:156033 AI 2002:1024
 PRAI US 2001-800266 AI 2001:0305 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 3220
 INCL INCLM: 514/044.000
 INCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
 NCL NCLM: 514/449.000; 514/509.000
 NCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-21; A61K039-00; A61K038-16

L10 ANSWER 6 OF 204 USPATFULL
 AN 2002:280561 USPATFULL
 TI Secreted and transmembrane polypeptides and nucleic acids encoding the same
 IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES
 Baker, Kevin P., Darnestown, MD, UNITED STATES
 Botstein, David, Belmont, CA, UNITED STATES
 Desnoyers, Luc, San Francisco, CA, UNITED STATES
 Eaton, Dan L., San Rafael, CA, UNITED STATES
 Ferrara, Napoleone, San Francisco, CA, UNITED STATES
 Filvaroff, Ellen, San Francisco, CA, UNITED STATES
 Fong, Sherman, Alameda, CA, UNITED STATES
 Gao, Wei-Qiang, Palo Alto, CA, UNITED STATES
 Gerber, Hanspeter, San Francisco, CA, UNITED STATES
 Gerritsen, Mary E., San Mateo, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Godowski, Paul J., Burlingame, CA, UNITED STATES
 Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Hillan, Kenneth J., San Francisco, CA, UNITED STATES
 Kijavini, Ivar J., Lafayette, CA, UNITED STATES
 Kuo, Sophia S., San Francisco, CA, UNITED STATES
 Napier, Mary A., Hillsborough, CA, UNITED STATES
 Pan, James, Belmont, CA, UNITED STATES
 Paoni, Nicholas F., Belmont, CA, UNITED STATES
 Roy, Margaret Ann, San Francisco, CA, UNITED STATES
 Shelton, David L., Oakland, CA, UNITED STATES
 Stewart, Timothy A., San Francisco, CA, UNITED STATES
 Tumas, Daniel, Orinda, CA, UNITED STATES
 Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES

Genentech, Inc. (U.S. corporation)
 PA US 2002:156006 AI 2002:1024
 PI US 2001-978295 AI 2001:1015 (9)
 AI Continuation of Ser. No. US 1998-40220, filed on 17 Mar 1998, PENDING
 RLI Continuation of Ser. No. US 1998-105413, filed on 26 Jun 1998, PENDING
 Continuation of Ser. No. US 1998-168978, filed on 7 Oct 1998, PENDING
 Continuation of Ser. No. US 1998-184216, filed on 2 Nov 1998, ABANDONED
 Continuation of Ser. No. US 1998-187368, filed on 6 Nov 1998, PENDING
 Continuation of Ser. No. US 1998-202054, filed on 7 Dec 1998, PENDING
 Continuation of Ser. No. US 1998-218517, filed on 22 Dec 1998, ABANDONED
 Continuation of Ser. No. US 1999-254465, filed on 5 Mar 1999, PENDING
 Continuation of Ser. No. US 1999-265686, filed on 10 Mar 1999, PENDING
 Continuation of Ser. No. US 1999-267213, filed on 12 Mar 1999, ABANDONED
 Continuation of Ser. No. US 1999-284291, filed on 12 Apr 1999, ABANDONED
 Continuation of Ser. No. US 1999-311832, filed on 14 May 1999, PENDING
 Continuation of Ser. No. US 380137, PENDING Continuation of Ser. No. US
 1999-380138, filed on 25 Aug 1999, PENDING Continuation of Ser. No. US
 1999-380142, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US
 2000-709238, filed on 8 Nov 2000, PENDING Continuation of Ser. No. US
 2000-723749, filed on 27 Nov 2000, PENDING Continuation of Ser. No. US
 2000-747259, filed on 20 Dec 2000, PENDING Continuation of Ser. No. US
 2001-816744, filed on 22 Mar 2001, PENDING Continuation of Ser. No. US
 2001-816920, filed on 22 Mar 2001, PENDING Continuation of Ser. No. US
 2001-854280, filed on 10 May 2001, PENDING Continuation of Ser. No. US
 2001-854298, filed on 10 May 2001, PENDING Continuation of Ser. No. US
 2001-874503, filed on 1 Jun 2001, PENDING Continuation of Ser. No. US
 2001-882035, filed on 5 Jun 2001, PENDING Continuation of Ser. No. US
 2001-882636, filed on 14 Jun 2001, PENDING Continuation of Ser. No. US
 2001-886342, filed on 19 Jun 2001, PENDING Continuation of Ser. No. US
 2001-918585, filed on 30 Jun 2001, PENDING
 PRAI WO 1998-US21141 1998:1007
 WO 1998-US24855 1998:1120
 WO 1999-US106 1999:0105
 WO 1999-US5028 1999:0308
 WO 1999-US5190 1999:0310
 WO 1999-US10733 1999:0514
 WO 1999-US12452 1999:0602
 WO 1999-US28313 1999:1130
 WO 1999-US28551 1999:1202
 WO 1999-US28565 1999:1202
 WO 1999-US30095 1999:1216
 WO 1999-US31243 1999:1230
 WO 1999-US31274 1999:1230
 WO 2000-US219 2000:0105
 WO 2000-US277 2000:0106
 WO 2000-US376 2000:0106
 WO 2000-US3555 2000:0211
 WO 2000-US4341 2000:0218
 WO 2000-US5841 2000:0302
 WO 2000-US7532 2000:0321
 WO 2000-US5034 2000:0224
 WO 2000-US6319 2000:0310
 WO 2000-US8439 2000:0330
 WO 2000-US13705 2000:0517
 WO 2000-US14042 2000:0522
 WO 2000-US14941 2000:0530
 WO 2000-US15264 2000:0602
 WO 2000-US20710 2000:0628
 WO 2000-US23328 2000:0628
 WO 2000-US32678 2000:1201
 WO 2000-US34956 2000:1220
 WO 2001-US6520 2001:0228
 WO 2001-US9552 2001:0322
 WO 2001-US17092 2001:0325
 WO 2001-US17800 2001:0601

WO 2001-US19692	20010620	PA	Tendler, Craig L., Teaneck, NJ, UNITED STATES
WO 2001-US21066	20010629	PI	Schering Corporation (2)
WO 2001-US21735	20010709	AI	US 2002151503 AI 20021017
US 1997-62250P	19971017 (60)	AI	US 2002-67443 AI 20020205 (10)
US 1997-64249P	19971103 (60)	PRAI	US 2001-267807P 20010209 (60)
US 1997-65311P	19971113 (60)	DT	Utility
US 1997-66364P	19971121 (60)	FS	APPLICATION
US 1998-77450P	19980310 (60)	LN.CNT	902
US 1998-77632P	19980311 (60)	INCL	INCLM: 514/034.000
US 1998-77641P	19980311 (60)	NCL	INCLS: 424/450.000
US 1998-77649P	19980311 (60)	NCL	NCLM: 514/034.000
US 1998-77791P	19980312 (60)	IC	NCLS: 424/450.000
US 1998-78004P	19980313 (60)		[7]
US 1998-78886P	19980320 (60)		ICM: A61K031-704
US 1998-78936P	19980320 (60)		ICS: A61K009-127
US 1998-78910P	19980320 (60)		
US 1998-78939P	19980320 (60)		
US 1998-79294P	19980325 (60)		
US 1998-79656P	19980326 (60)		
US 1998-79664P	19980327 (60)		
US 1998-79689P	19980327 (60)		
US 1998-79663P	19980327 (60)		
US 1998-79728P	19980327 (60)		
US 1998-79786P	19980327 (60)		
US 1998-79920P	19980330 (60)		
US 1998-79923P	19980330 (60)		
DT			
FS			
APPLICATION			
LN.CNT	4995		
INCL	INCLM: 514/012.000		
	INCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;		
	435/183.000; 435/320.100; 435/325.000		
NCL	NCLM: 514/012.000		
	NCLS: 530/350.000; 530/388.100; 536/023.200; 435/007.100; 435/069.100;		
	435/183.000; 435/320.100; 435/325.000		
IC	[7]		
ICM: A61K038-17			
ICS: G01N033-53; C07H021-04; C12N009-00; C12P021-02; C12N005-06;			
C07K014-435; C07K016-40			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
LN10	ANSWER 7 OF 204	USPATFULL	
AN	2002:280029	USPATFULL	
TI	Prostate polynucleotides and uses		
IN	Sun, Zairen, Rockville, MD, UNITED STATES		
	Li, Xuan, Silver Spring, MD, UNITED STATES		
	Jay, Gilbert, North Bethesda, MD, UNITED STATES		
PI	US 2002153463 AI 20021024		
AI	US 2001-996956 AI 20011130 (9)		
PRAI	US 2000-250354P 20001201 (60)		
DT	Utility		
FS	APPLICATION		
LN.CNT	2288		
INCL	INCLM: 435/006.000		
	INCLS: 536/024.300; 536/023.200		
NCL	NCLM: 435/006.000		
	NCLS: 536/024.300; 536/023.200		
IC	[7]		
ICM: C12Q001-68			
ICS: C07H021-04			
LN10	ANSWER 8 OF 204	USPATFULL	
AN	2002:273380	USPATFULL	
TI	Methods for treating proliferative diseases		
IN	Emanuel, David J., Tenafly, NJ, UNITED STATES		
PA	US 2002151503 AI 20021017		
AI	US 2002-67443 AI 20020205 (10)		
PRAI	US 2001-267807P 20010209 (60)		
DT	Utility		
FS	APPLICATION		
LN.CNT	902		
INCL	INCLM: 514/034.000		
	INCLS: 424/450.000		
NCL	NCLM: 514/034.000		
	NCLS: 424/450.000		
IC	[7]		
ICM: A61K031-704			
ICS: A61K009-127			
LN10	ANSWER 9 OF 204	USPATFULL	
AN	2002:272474	USPATFULL	
TI	Compositions for treatment of melanoma and method of using same		
IN	Houghton, Alan N., New York, NY, UNITED STATES		
	Bergman, Philip J., Tarrytown, NY, UNITED STATES		
	Wolchok, Jedd D., New York, NY, UNITED STATES		
PI	US 2002150589 AI 20021017		
AI	US 2001-996128 AI 20011127 (9)		
RLI	Continuation-in-part of Ser. No. US 2000-627694, filed on 28 Jul 2000.		
	PENDING Continuation-in-part of Ser. No. US 1999-308697, filed on 21 May		
	1999, GRANTED, Pat. No. US 6328969 A 371 of International Ser. No. WO		
PRAI	US 1997-36419P 19970218 (60)		
	US 1996-32535P 19961210 (60)		
	US 2000-180651P 20000126 (60)		
DT	Utility		
FS	APPLICATION		
LN.CNT	780		
INCL	INCLM: 424/185.100		
	INCLS: 435/226.000		
NCL	NCLM: 424/185.100		
	NCLS: 435/226.000		
IC	[7]		
ICM: A61K039-00			
ICS: C12N009-64			
LN10	ANSWER 10 OF 204	USPATFULL	
AN	2002:266439	USPATFULL	
TI	NSP molecules		
IN	Stewart, Timothy A., San Francisco, CA, UNITED STATES		
	Lu, Yamei, Foster City, CA, UNITED STATES		
PA	Genentech, Inc. (U.S. corporation)		
PI	US 2002147322 AI 20021010		
AI	US 2001-931087 AI 20010815 (9)		
RLI	Division of Ser. No. US 1999-367206, filed on 9 Aug 1999, PATENTED		
PRAI	WO 1999-US8847 19990423		
	US 1998-82767P 19980423 (60)		
	US 1998-113296P 19981222 (60)		
DT	Utility		
FS	APPLICATION		
LN.CNT	6046		
INCL	INCLM: 536/023.200		
	INCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;		
	435/183.000		
NCL	NCLM: 536/023.200		
	NCLS: 435/006.000; 435/007.230; 435/325.000; 435/320.100; 435/069.100;		
	435/183.000		
IC	[7]		
ICM: C07H021-04			

ICS: C120001-68; GO1N033-574; C12P021-02; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 204 USPTFULL
AN 2002:265970 USPTFULL
TI Novel method for the stabilization of chimeric immunoglobulins or
immunoglobulin fragments, and stabilized anti-EGF-2 scfv fragment
IN Pluckhuhn, Andreas, Zurich, SWITZERLAND
Honegger, Annemarie, Zurich, SWITZERLAND
Willuda, Jörg, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2002:146846 A1 20021010
AI US 2001-971543 A1 20011004 (9)
RLI Continuation of Ser. No. WO 2000-EP3176, filed on 10 Apr 2000, UNKNOWN
PRAI EP 1999-107030 19990409
DT Utility
FS APPLICATION

LN.CNT 1663
INCL INCLM: 436/518.000
INCLS: 702/019.000; 435/069.100
NCL NCLM: 436/518.000
NCLS: 702/019.000; 435/069.100
IC [7]
ICM: GO1N033-543

ICS: G06F019-00; GO1N033-48; GO1N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 204 USPTFULL
AN 2002:265931 USPTFULL
TI Cardiotropin-1 compositions and methods for the treatment of tumor
IN Botstein, David, Belmont, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Lawrence, David A., San Francisco, CA, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Roy, Margaret Ann, San Francisco, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Genentech, Inc. (U.S. corporation)
PI US 2002:146707 A1 20021010
AI US 2001-901257 A1 20010709 (9)
RLI Continuation of Ser. No. US 2000-648252, filed on 25 Aug 2000, ABANDONED

Division of Ser. No. US 1999-234730, filed on 21 Jan 1999, ABANDONED
Division of Ser. No. US 1998-33114, filed on 2 Mar 1998, ABANDONED
Continuation of Ser. No. US 1996-733850, filed on 18 Oct 1996, ABANDONED
Continuation of Ser. No. US 1995-443129, filed on 17 May 1995, GRANTED,
Pat. No. US 5627073 Division of Ser. No. US 1994-286304, filed on 5 Aug
1994, GRANTED, Pat. No. US 5571893 Continuation-in-part of Ser. No. US
1994-233609, filed on 25 Apr 1994, GRANTED, Pat. No. US 5534615
PRAI US 1998-113298P 19981222 (60)
DT Utility
FS APPLICATION

LN.CNT 3565
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 536/023.200
IC [7]
ICM: C120001-68

ICS: GO1N033-574; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 204 USPTFULL
AN 2002:259486 USPTFULL
TI Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
IN Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
Tari, Ana M., Houston, TX, UNITED STATES
Lim, Soo-Jeong, Seoul, KOREA, REPUBLIC OF

PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002:143062 A1 20021003
AI US 2001-982113 A1 20011017 (9)
PRAI US 2000-241445P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3985
INCL INCLM: 514/613.000
INCLS: 424/155.100; 424/450.000
NCL NCLM: 514/613.000
NCLS: 424/155.100; 424/450.000
IC [7]
ICM: A61K039-395
ICS: A61K031-16; A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 204 USPTFULL
AN 2002:258758 USPTFULL
TI Method of determining a chemotherapeutic regimen by assaying
gene expression in primary tumors
IN Danenberg, Kathleen D., Altadena, CA, UNITED STATES
PI US 2002:142328 A1 20021003
AI US 2001-998333 A1 20011203 (9)
PRAI US 2000-250120P 20001201 (60)
DT Utility
FS APPLICATION

LN.CNT 1617
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C120001-68

ICS: G06F019-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 204 USPTFULL
AN 2002:258426 USPTFULL
TI Apo-2 ligand-anti-Her-2 antibody synergism
IN Ashkenazi, Avi J., San Mateo, CA, UNITED STATES
Phillips, Gail Lewis, San Carlos, CA, UNITED STATES
GENENTECH, INC. (U.S. corporation)
PI US 2002:141993 A1 20021003
AI US 2002-107958 A1 20020326 (10)
RLI Continuation of Ser. No. US 1999-277252, filed on 26 Mar 1999, PENDING
PRAI US 1998-79683P 19980327 (60)
DT Utility
FS APPLICATION

LN.CNT 1596
INCL INCLM: 424/143.100
INCLS: 424/155.100; 600/001.000
NCL NCLM: 424/143.100
NCLS: 424/155.100; 600/001.000
IC [7]
ICM: A61K039-395

ICS: A61N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 204 USPTFULL
AN 2002:258375 USPTFULL
TI PSCA: prostate stem cell antigen and uses thereof
IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
Witte, Owen N., Sherman Oaks, CA, UNITED STATES
Saffran, Douglas C., Los Angeles, CA, UNITED STATES

PA Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
The Regents of the University of California and UroGenesys, Inc. (U.S. corporation)

PI US 2002141941 A1 20021003
US 2001-963620 A1 20010926 (9)

RLI Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
1999, PATENTED Continuation-in-part of Ser. No. US 1999-251835, filed on
17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1997-228816P 19970310 (60)
US 1998-71141P 19980112 (60)
US 1998-74675P 19980213 (60)
US 1998-113230P 19981221 (60)
US 1999-120536P 19990217 (60)
US 1999-124658P 19990316 (60)

DT Utility
FS APPLICATION

LN.CNT 5010
INCL INCLM: 424/001.490
INCLS: 424/155.100; 424/178.100
NCL NCLM: 424/001.490
NCLS: 424/155.100; 424/178.100

IC [7]
ICM: A61K051-00
ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 204 USPTATFULL
AN 2002:251802 USPTATFULL

TI Tyrosine kinase inhibitors

IN Bilodeau, Mark T., Lansdale, PA, UNITED STATES
Hoffman, George D., Lansdale, PA, UNITED STATES
Hoffman, Jacob M., JR., Lansdale, PA, UNITED STATES
Sisko, John T., Lansdale, PA, UNITED STATES
Manley, Peter J., Harleysville, PA, UNITED STATES
Smith, Anthony M., Green Lane, PA, UNITED STATES
Tucker, Thomas J., North Wales, PA, UNITED STATES
Lumma, William C., JR., Helena, MT, UNITED STATES
Rodman, Leonard, New York, NY, UNITED STATES

PI US 2002137755 A1 20020926
US 2001-990473 A1 20011121 (9)

PRAI US 2000-251006P 20001204 (60)

DT Utility
FS APPLICATION

LN.CNT 3627
INCL INCLM: 514/256.000
INCLS: 514/269.000; 544/317.000; 544/327.000; 544/328.000
NCL NCLM: 514/256.000
NCLS: 514/269.000; 544/317.000; 544/327.000; 544/328.000

IC [7]
ICM: A61K031-506
ICS: C07D417-02; C07D413-02; C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 204 USPTATFULL
AN 2002:251730 USPTATFULL

TI C-eki oncogene-derived peptides for prevention, treatment, and diagnosis
of cancer

IN Hogan, Kevin T., Charlottesville, VA, UNITED STATES
Ross, Mark M., Charlottesville, VA, UNITED STATES

PI US 2002137683 A1 20020926

AI US 2001-753831 A1 20010103 (9)

PRAI US 2000-174236P 20000103 (60)

DT Utility
FS APPLICATION

LN.CNT 2293
INCL INCLM: 514/015.000
INCLS: 514/044.000; 536/023.100; 530/328.000
NCL NCLM: 514/015.000
NCLS: 514/044.000; 536/023.100; 530/328.000

IC [7]
ICM: A61K048-00
ICS: A61K038-08; C07H021-04; C07K007-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 204 USPTATFULL
AN 2002:250751 USPTATFULL

TI PSCA: prostate stem cell antigen and uses thereof

IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
Witte, Owen N., Sherman Oaks, CA, UNITED STATES
Saffran, Douglas C., Los Angeles, CA, UNITED STATES
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
The Regents of the University of California (U.S. corporation)

PA US 2002136689 A1 20020926
US 2001-934773 A1 20010821 (9)

RLI Continuation of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1997-228816P 19970310 (60)
US 1998-71141P 19980112 (60)
US 1998-74675P 19980213 (60)
US 1998-113230P 19981221 (60)
US 1999-120536P 19990217 (60)
US 1999-124658P 19990316 (60)

DT Utility
FS APPLICATION

LN.CNT 5011
INCL INCLM: 424/001.490
INCLS: 424/155.100; 424/178.100; 530/388.800; 530/391.100
NCL NCLM: 424/001.490
NCLS: 424/155.100; 424/178.100; 530/388.800; 530/391.100

IC [7]
ICM: A61K051-00
ICS: A61K039-395; C07K016-30; C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 204 USPTATFULL
AN 2002:243088 USPTATFULL

TI Diagnostic and monitorings methods for cancer

IN Nevalainen, Marja T., Rockville, MD, UNITED STATES
Rui, Hallgeir, Rockville, MD, UNITED STATES

PI US 2002132274 A1 20020919

AI US 2001-760899 A1 20010117 (9)

DT Utility
FS APPLICATION

LN.CNT 3189
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230

IC [7]
ICM: G01N033-574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 204 USPTATFULL

AN 2002:243038 USPTATFULL
 TI Car receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
 IN Poznansky, Mark C., Charlestown, MA, UNITED STATES
 Sadden, David T., Weston, MA, UNITED STATES
 Olazak, Ivona T., Charlestown, MA, UNITED STATES
 Brown, Edward M., Milton, MA, UNITED STATES
 US 2002:132224 AI 20020919
 PI US 2001:2854 AI 20011101 (10)
 RLI Continuation-in-part of Ser. No. WO 2000-US15440, filed on 2 Jun 2000,
 UNKNOWN
 DT Utility
 FS APPLICATION
 LN.CNT 2510
 INCL INCLM: 435/004.000
 INCLS: 514/001.000
 NCL NCLM: 435/004.000
 NCLS: 514/001.000
 IC [7]
 ICM: A61K031-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 204 USPTATFULL
 AN 2002:236082 USPTATFULL
 TI Methods of inducing cancer cell death and tumor regression
 IN Daley, George Q., Weston, MA, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 2002:28280 AI 20020912
 AI US 2001:971545 AI 20011005 (9)
 PRAI US 2000:238240P 20001005 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1314
 INCL INCLM: 514/275.000
 INCLS: 514/290.000
 NCL NCLM: 514/275.000
 NCLS: 514/290.000
 IC [7]
 ICM: A61K031-505
 ICS: A61K031-473
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 204 USPTATFULL
 AN 2002:235993 USPTATFULL
 TI Expression of properly folded and soluble extracellular domain of a gonadotropin receptor
 IN Lebel, Leslie, Riverdale, NY, UNITED STATES
 PI Lustbader, Joyce, Tenafly, NJ, UNITED STATES
 AI US 2002:28190 AI 20020912
 AI US 2001:804626 AI 20010309 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 2879
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 NCL NCLM: 514/012.000
 NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 IC [7]
 ICM: A61K038-00
 ICS: C12P021-02; C12N005-06; C07H021-04; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 24 OF 204 USPTATFULL
 AN 2002:227938 USPTATFULL
 TI Novel inhibitor of hepatocyte growth factor activator for use in

IN modulation of angiogenesis and cardiovascularization
 Gurney, Austin L., Belmont, CA, UNITED STATES
 Kirchofer, Daniel K., Los Altos, CA, UNITED STATES
 Wood, William I., Hilleborough, CA, UNITED STATES
 GENENTECH, INC. (U.S. corporation)
 PA US 2002:123031 AI 20020905
 PI US 2000:742291 AI 20001219 (9)
 AI WO 2000-US3555 20000211
 PRAI WO 2000-US6834 20000315
 US 2000-253655P 20001128 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6377
 INCL INCLM: 435/069.100
 INCLS: 514/002.000; 435/007.210; 530/387.900; 435/320.100; 514/044.000;
 NCL NCLM: 435/069.100
 NCLS: 514/002.000; 435/007.210; 530/387.900; 435/320.100; 514/044.000;
 IC [7]
 ICM: A01N037-18
 ICS: A61K038-00; G01N033-567; C07H021-04; A61K031-70; A01N043-04;
 C12P021-06; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74;
 C12N005-00; C12N005-02; C07K016-00; C12P021-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 25 OF 204 USPTATFULL
 AN 2002:227642 USPTATFULL
 TI Heparinase III and uses thereof
 IN Liu, Dongfang, Framingham, MA, UNITED STATES
 Pojasek, Kevin, Cambridge, MA, UNITED STATES
 Shriver, Zachary, Cambridge, MA, UNITED STATES
 Holley, Kristine, Boston, MA, UNITED STATES
 El-Shabrawi, Yusuf, Graz, AUSTRIA
 Venkataraman, Ganesh, Wallham, MA, UNITED STATES
 Saeisekharan, Ram, Cambridge, MA, UNITED STATES
 PI US 2002:122793 AI 20020905
 AI US 2001-802285 AI 20010308 (9)
 PRAI US 2000-187846P 20000308 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3154
 INCL INCLM: 424/094.610
 NCL NCLM: 424/094.610
 IC [7]
 ICM: A61K038-47
 ICS: C12N003-24
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 26 OF 204 USPTATFULL
 AN 2002:221022 USPTATFULL
 TI PSCA: prostate stem cell antigen and uses thereof
 IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
 Witte, Owen N., Sherman Oaks, CA, UNITED STATES
 Saffran, Douglas C., Los Angeles, CA, UNITED STATES
 Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
 PI US 2002:119157 AI 20020829
 AI US 2001-854611 AI 20010514 (9)
 RLI Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
 1999, PATENTED Continuation-in-part of Ser. No. US 1999-251835, filed on
 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
 filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
 1998-38261, filed on 10 Mar 1998, PATENTED

PRAI US 1999-124658P 19990316 (60)
 US 1999-120536P 19990217 (60)
 US 1998-113230P 19981221 (60)
 US 1998-74675P 19980213 (60)
 US 1998-71141P 19980112 (60)
 US 1997-228816P 19970310 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5019
 INCL INCLM: 424/155.100
 INCLS: 530/388.800
 NCL INCLM: 424/155.100
 NCLM: 530/388.800
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-30
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 27 OF 204 USPATFULL
 AN 2002:213689 USPATFULL
 TI Differentially expressed epitopes and uses thereof
 IN Logtenberg, Ton, Werkhoven, NETHERLANDS
 Cilenti, Lucia, Rome, ITALY
 Bloem, Andries Christiaan, Driebergen, NETHERLANDS
 Zwijssen, Renate Marie Louise, Utrecht, NETHERLANDS
 PI US 2002115065 A1 20020822
 AI US 2001-940386 A1 20010827 (9)
 PRAI US 2000-228429P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2795
 INCL INCLM: 435/005.000
 INCLS: 435/007.100; 435/007.210; 435/007.320; 435/006.000
 NCL INCLM: 435/005.000
 NCLM: 435/007.100; 435/007.210; 435/007.320; 435/006.000
 IC [7]
 ICM: C12Q001-70
 ICS: C12Q001-68; G01N033-53; G01N033-567; G01N033-554; G01N033-569
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 28 OF 204 USPATFULL
 AN 2002:205851 USPATFULL
 TI Methods and products for tumor immunotherapy using cytokines
 IN Mathowitz, Edith, Brookline, MA, UNITED STATES
 Jong, Yong S., Providence, RI, UNITED STATES
 Eglmezt, Nejat K., E. Amherst, NY, UNITED STATES
 Bankert, Richard B., Eden, NY, UNITED STATES
 PA Jacob, Jules S., Taunton, MA, UNITED STATES
 Health Research, Inc. (U.S. Corporation)
 PI US 2002110538 A1 20020815
 AI US 2000-749649 A1 20001227 (9)
 PRAI US 1999-173236P 19991228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1955
 INCL INCLM: 424/085.100
 INCLS: 424/491.000
 NCL INCLM: 424/085.100
 NCLM: 424/491.000
 IC [7]
 ICM: A61K038-19
 ICS: A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 29 OF 204 USPATFULL

AN 2002:191601 USPATFULL
 TI PSCA: prostate stem cell antigen and uses thereof
 IN Reiter, Robert E., Los Angeles, CA, UNITED STATES
 Witte, Owen N., Sherman Oaks, CA, UNITED STATES
 Saffran, Douglas C., Los Angeles, CA, UNITED STATES
 Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
 PA The Regents of the University of California (U.S. corporation)
 PI US 2002102666 A1 20020801
 AI US 2001-855153 A1 20010514 (9)
 RLI Division of Ser. No. US 2000-564329, filed on 3 May 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-359326, filed on 20 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-318503, filed on 25 May
 1999, PATENTED Continuation-in-part of Ser. No. US 1999-251835, filed on
 17 Feb 1999, PATENTED Continuation-in-part of Ser. No. US 1998-203939,
 filed on 2 Dec 1998, PATENTED Continuation-in-part of Ser. No. US
 1998-38261, filed on 10 Mar 1998, PATENTED
 PRAI US 1997-228816P 19970310 (60)
 US 1998-71141P 19980112 (60)
 US 1998-74675P 19980213 (60)
 US 1998-113230P 19981221 (60)
 US 1999-120536P 19990217 (60)
 US 1999-124658P 19990316 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5002
 INCL INCLM: 435/110.000
 INCLS: 424/178.100; 424/001.490; 530/389.100
 NCL INCLM: 435/110.000
 NCLM: 424/178.100; 424/001.490; 530/389.100
 IC [7]
 ICM: A61K039-395
 ICS: A61K051-00; C07K016-46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L10 ANSWER 30 OF 204 USPATFULL
 AN 2002:191557 USPATFULL
 TI Cardiotrophin-1 compositions and methods for the treatment of tumor
 IN Botstein, David, Belmont, CA, UNITED STATES
 Goddard, Audrey, San Francisco, CA, UNITED STATES
 Lawrence, David A., San Francisco, CA, UNITED STATES
 Pennica, Diane, Burlingame, CA, UNITED STATES
 Roy, Margaret Ann, San Francisco, CA, UNITED STATES
 Wood, William I., Hillsborough, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 2002102622 A1 20020801
 AI US 2001-901540 A1 20010709 (9)
 RLI Continuation of Ser. No. US 2000-648258, filed on 25 Aug 2000, ABANDONED
 Division of Ser. No. US 1999-234730, filed on 21 Jan 1999, ABANDONED
 Continuation of Ser. No. US 1998-33114, filed on 2 Mar 1998, ABANDONED
 Continuation of Ser. No. US 1996-733850, filed on 18 Oct 1996, ABANDONED
 Continuation of Ser. No. US 1995-443129, filed on 17 May 1995, PATENTED
 Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, PATENTED
 Continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994,
 PATENTED
 PRAI US 1998-113296P 19981222 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3559
 INCL INCLM: 435/007.230
 INCLS: 435/226.000; 435/069.100; 435/252.300; 435/254.100; 435/325.000;
 435/320.100; 536/023.200
 NCL INCLM: 435/007.230
 NCLM: 435/226.000; 435/069.100; 435/252.300; 435/254.100; 435/325.000;
 435/320.100; 536/023.200
 IC [7]

ICM: G01N033-574
ICS: C07H021-04; C12N009-64; C12N001-18; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 204 USPATFULL
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Mine Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bouguieret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002:102604 A1 2002:0801
AI US 2000-731872 A1 2000:1207 (9)
PRAI US 1999-169629P 1999:1208 (60)
US 2000-187470P 2000:0306 (60)
DT Utility
FS APPLICATION
LN.CNT 28061
INCL INCLM: 435/007.100
INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 204 USPATFULL
AN 2002:191479 USPATFULL
TI Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
IN Mack, David, Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
Wilson, Keith E., Redwood City, CA, UNITED STATES
PI US 2002:102544 A1 2002:0801
AI US 2000-733757 A1 2000:1208 (9)
RLI Continuation-in-part of Ser. No. US 2000-663733, filed on 15 Sep 2000.
DT PENDING
FS Utility
FS APPLICATION
LN.CNT 3191
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 204 USPATFULL
AN 2002:191201 USPATFULL
TI Uses of monoclonal antibody 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002:102264 A1 2002:0801
AI US 2001-982645 A1 2001:1018 (9)
PRAI US 2000-241344P 2000:1018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
INCLS: 424/178.100; 530/389.100; 435/326.000
NCL NCLM: 424/155.100
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]

ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 204 USPATFULL
AN 2002:185279 USPATFULL
TI Vascular endothelial cell growth factor antagonists
IN Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Kim, Kyung Jin, San Francisco, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2002:098187 A1 2002:0725
AI US 2002-104427 A1 2002:0321 (10)
RLI Continuation of Ser. No. US 1997-970591, filed on 14 Nov 1997, ABANDONED
Continuation-in-part of Ser. No. US 1995-378912, filed on 25 Jan 1995,
ABANDONED Continuation of Ser. No. US 1993-143308, filed on 26 Oct 1993,
ABANDONED Continuation of Ser. No. US 1992-968028, filed on 28 Oct 1992,
ABANDONED Continuation-in-part of Ser. No. US 1991-677215, filed on 29
Mar 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1258
INCL INCLM: 424/145.100
NCL NCLM: 424/145.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 204 USPATFULL
AN 2002:171960 USPATFULL
TI Modified carboxypeptidase enzymes and their use
IN Begent, Richard H. J., London, UNITED KINGDOM
Chester, Kerry, London, UNITED KINGDOM
Minton, Nigel P., Wiltshire, UNITED KINGDOM
Rees, Anthony R., Bath, UNITED KINGDOM
Sharma, Surinder K., London, UNITED KINGDOM
Spencer, Daniel I. R., Hertfordshire, UNITED KINGDOM
PI US 2002:090709 A1 2002:0711
AI US 2001-698461 A1 2001:0705 (9)
PRAI US 2000-216689P 2000:0707 (60)
DT Utility
FS APPLICATION
LN.CNT 1212
INCL INCLM: 435/236.000
INCLS: 435/069.700; 435/320.100; 435/325.000; 536/023.200; 435/254.200
NCL NCLM: 435/236.000
NCLS: 435/069.700; 435/320.100; 435/325.000; 536/023.200; 435/254.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-04; C12N001-18; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 204 USPATFULL
AN 2002:164793 USPATFULL
TI Agents for treating malignant diseases using the protein YB-1
IN Holm, Per Sonne, Munchen, GERMANY, FEDERAL REPUBLIC OF
Royer, Hans-Dieter, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
Dietel, Manfred, Berlin, GERMANY, FEDERAL REPUBLIC OF
Lage, Hermann, Berlin, GERMANY, FEDERAL REPUBLIC OF
Ladhoff, Axel, Bergfelde, GERMANY, FEDERAL REPUBLIC OF
Jurchoff, Karsten, Altlandsberg, GERMANY, FEDERAL REPUBLIC OF
Bergmann, Stephan, Berlin, GERMANY, FEDERAL REPUBLIC OF
Brand, Karsten, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2002:086411 A1 2002:0704
US 2001-29574 A1 2001:1220 (10)
RLI Continuation-in-part of Ser. No. WO 2000-DE1978, filed on 20 Jun 2000,

PA	UNKNOWN		
DE	1999-19929569	19990621	
DT	UTILITY		
FS	APPLICATION		
LN.CNT	354		
INCL	INCLM: 435/235.100		
NCL	INCLS: 424/093.210; 435/456.000		
NCLM	435/235.100		
NCLS	424/093.210; 435/456.000		
IC	[7]		
ICM:	A61K048-00		
ICS:	C12N007-00		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
L10	ANSWER 37 OF 204 USPATFULL		
AN	2002:164666 USPATFULL		
TI	Methods for the treatment of cellular proliferative disorders		
IN	Coffey, Matthew C., Calgary, CANADA		
PI	US 2002086284 A1 20020704		
AI	US 2001-985756 A1 20011106 (9)		
PRAI	US 2000-246728P 20001109 (60)		
DT	UTILITY		
FS	APPLICATION		
LN.CNT	1374		
INCL	INCLM: 435/005.000		
NCL	INCLS: 435/007.230		
NCLM	435/005.000		
NCLS	435/007.230		
IC	[7]		
ICM:	C12Q001-70		
ICS:	G01N033-574		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
L10	ANSWER 38 OF 204 USPATFULL		
AN	2002:133829 USPATFULL		
TI	Methods and compositions for inhibiting cell proliferative disorders		
IN	Chen, Hui, Palo Alto, CA, UNITED STATES		
	Gazit, Aviv, Jerusalem, ISRAEL		
	Levitzki, Alexander, Jerusalem, ISRAEL		
	Hirth, Klaus Peter, San Francisco, CA, UNITED STATES		
	Mann, Elaine, Alameda, CA, UNITED STATES		
	Shawver, Laura K., San Francisco, CA, UNITED STATES		
	Tsang, Feng Cho, Moraga, CA, UNITED STATES		
PI	US 2002068687 A1 20020606		
AI	US 2001-953933 A1 20010918 (9)		
RLI	Continuation of Ser. No. US 2000-722149, filed on 22 Nov 2000, ABANDONED		
	Continuation of Ser. No. US 1998-70318, filed on 29 Apr 1998, ABANDONED		
	Continuation of Ser. No. US 1995-399967, filed on 7 Mar 1995, PATENTED		
	Continuation-in-part of Ser. No. US 1994-207933, filed on 7 Mar 1994, ABANDONED		
DT	UTILITY		
FS	APPLICATION		
LN.CNT	2876		
INCL	INCLM: 510/433.000		
NCL	NCLM: 510/433.000		
IC	[7]		
ICM:	C11D017-00		
L10	ANSWER 39 OF 204 USPATFULL		
AN	2002:133430 USPATFULL		
TI	Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer		
IN	An, Gang, Oklahoma City, OK, UNITED STATES		
	Veitri, Robert, Oklahoma City, OK, UNITED STATES		

UROCOR, INC. (U.S. corporation)
 US 2002068281 A1 20020606
 Division of Ser. No. US 2001-754016 A1 20010102 (9)
 NO. US 6156515 Division of Ser. No. US 2000-579236, filed on 24 May 2000, PENDING
 UTILITY
 FS APPLICATION
 LN.CNT 3955
 INCL INCLM: 435/006.000
 INCLS: 435/089.100; 435/325.000; 435/320.100; 536/023.200
 NCL NCLM: 435/006.000
 NCLS: 435/089.100; 435/325.000; 435/320.100; 536/023.200
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 204 USPATFULL
 AN 2002:133200 USPATFULL
 TI Tissue specific adenoviral vectors
 IN Henderson, Daniel R., Palo Alto, CA, UNITED STATES
 Schuur, Eric R., Palo Alto, CA, UNITED STATES
 PI US 2002068049 A1 20020606
 AI US 2000-732169 A1 20001206 (9)
 RLI Continuation of Ser. No. US 1998-151376, filed on 10 Sep 1998, UNKNOWN
 DT Utility
 FS APPLICATION
 LN.CNT 3956
 INCL INCLM: 424/093.210
 INCLS: 435/235.100; 435/320.100
 NCL NCLM: 424/093.210
 NCLS: 435/235.100; 435/320.100
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-861
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 234 USPATFULL
 AN 2002:126293 USPATFULL
 TI Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies
 IN Akita, Robert, Hayward, CA, UNITED STATES
 Sliwowski, Mark, San Carlos, CA, UNITED STATES
 Genentech, Inc. (U.S. corporation)
 PI US 2002064805 A1 20020530
 AI US 2001-825594 A1 20010404 (9)
 RLI Division of Ser. No. US 1999-316981, filed on 24 May 1999, ABANDONED
 Continuation of Ser. No. US 1997-827009, filed on 25 Mar 1997, PATENTED
 PRAI US 1996-46850P 19960327 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2149
 INCL INCLM: 435/007.230
 INCLS: 424/141.100; 530/388.220
 NCL NCLM: 435/007.230
 NCLS: 424/141.100; 530/388.220
 IC [7]
 ICM: G01N033-574
 ICS: A61K039-395; C07K016-28
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 42 OF 204 USPATFULL
 AN 2002:126273 USPATFULL
 TI Gene detection assay for improving the likelihood of an effective

response to an ErbB antagonist cancer therapy
 IN Mass, Robert D., Mill Valley, CA, UNITED STATES
 PA Genentech Inc. (U.S. corporation)
 PI US 2002064785 AI 20020530
 AI US 2001-863101 AI 20010518 (9)
 PRAI US 2000-205754P 20000519 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1329
 INCL INCLM: 435/006.000
 INCL INCL: 435/007.230; 514/449.000
 NCL INCLM: 435/006.000
 NCL INCL: 435/007.230; 514/449.000
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-574; A61K031-337
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 204 USPTFULL
 AN 2002:119330 USPTFULL
 TI Compositions and methods for dendritic cell-based immunotherapy
 IN Laus, Reiner, Bellevue, WA, UNITED STATES
 IN Vigovic, Damir, Bellevue, WA, UNITED STATES
 Graddis, Thomas, Seattle, WA, UNITED STATES
 PI US 2002061310 AI 20020523
 AI US 2001-821883 AI 20010330 (9)
 PRAI US 2000-193504P 20000330 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2865
 INCL INCLM: 424/185.100
 INCL INCL: 530/350.000
 NCL INCLM: 424/185.100
 NCL INCL: 530/350.000
 IC [7]
 ICM: A61K039-00
 ICS: C07K014-435
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 44 OF 204 USPTFULL
 AN 2002:105676 USPTFULL
 TI Anti-IgE antibodies
 IN Lowman, Henry B., El Granada, CA, UNITED STATES
 Presta, Leonard G., San Francisco, CA, UNITED STATES
 Jardieu, Paula M., San Mateo, CA, UNITED STATES
 Lowe, John, Daly City, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 2002054878 AI 20020509
 AI US 2001-920171 AI 20010801 (9)
 RLI Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED,
 Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2
 Jul 1997, GRANTED, Pat. No. US 5994511
 DT Utility
 FS APPLICATION
 LN.CNT 5846
 INCL INCLM: 424/171.100
 INCL INCL: 424/130.100; 424/133.100; 435/023.530; 435/007.100; 530/387.300
 NCL INCLM: 424/171.100
 NCL INCL: 424/130.100; 424/133.100; 435/023.530; 435/007.100; 530/387.300
 IC [7]
 ICM: G01N033-53
 ICS: C07H021-04; A61K039-395; A61K039-40; A61K039-42; C12P021-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 45 OF 204 USPTFULL

2002:99468 USPTFULL
 AN Indolone derivatives as protein kinase/phosphatase inhibitors
 TI Tang, Peng Cho, Moraga, CA, UNITED STATES
 IN Harris, G. Davis, San Francisco, CA, UNITED STATES
 Li, Xiaoyuan, Los Altos, CA, UNITED STATES
 PI US 200202389 AI 20020502
 AI US 2001-871700 AI 20010604 (9)
 PRAI US 2000-209162P 20000602 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6105
 INCL INCLM: 514/233.500
 INCL INCL: 514/414.000; 435/007.100; 544/144.000; 548/468.000
 NCL INCLM: 514/233.500
 NCL INCL: 514/414.000; 435/007.100; 544/144.000; 548/468.000
 IC [7]
 ICM: A61K031-5377
 ICS: A61K031-404; C07D413-02; C07D043-02; G01N033-53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 46 OF 204 USPTFULL
 AN 2002:99407 USPTFULL
 TI Nucleic acids, proteins and antibodies
 IN Rosen, Craig A., Laytonville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 PI US 2002023208 AI 20020502
 AI US 2001-925301 AI 20010810 (9)
 RLI Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN
 PRAI US 1999-124270P 19990312 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 30577
 INCL INCLM: 514/001.000
 INCL INCL: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
 NCL INCLM: 530/350.000; 435/320.100; 435/325.000
 NCL INCLM: 514/001.000
 NCL INCL: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
 IC [7]
 ICM: A61K031-00
 ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435;
 C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 47 OF 204 USPTFULL
 AN 2002:98890 USPTFULL
 TI HER -2/neu overexpression abrogates growth inhibitory pathways
 IN Slamon, Dennis J., Woodland Hills, CA, UNITED STATES
 Wilson, Cindy A., Los Angeles, CA, UNITED STATES
 Calzone, Frank J., Westlake Village, CA, UNITED STATES
 PA The Regents of the University of California and Amgen Inc. (U.S.
 corporation)
 PI US 2002051785 AI 20020502
 AI US 2001-813517 AI 20010320 (9)
 PRAI US 2000-190598P 20000320 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2765
 INCL INCLM: 424/145.100
 INCL INCL: 514/044.000
 NCL INCLM: 424/145.100
 NCL INCL: 514/044.000
 IC [7]
 ICM: A61K039-395
 ICS: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 48 OF 204 USPATFULL
AN 2002:92782 USPATFULL
TI Novel macrocyclic magnetic resonance imaging contrast agents
IN Hubin, Timothy J., McPherson, KS, UNITED STATES
PI Meade, Thomas J., Altadena, CA, UNITED STATES
AI US 2002049308 A1 20020425
PRAI US 2001-908436 A1 20010717 (9)
FS US 2000-218581P 20000717 (60)
DT Utility
FS APPLICATION
LN.CNT 984
INCL INCLM: 534/015.000
INCL INCLS: 540/472.000
NCL NCLM: 534/015.000
NCL NCLS: 540/472.000
IC [7]
ICM: C07F005-00
ICS: C07D487-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 49 OF 204 USPATFULL
AN 2002:92295 USPATFULL
TI Methods and products for regulating cell motility
IN Gertler, Frank B., Boston, MA, UNITED STATES
IN Bear, James E., Brighton, MA, UNITED STATES
Loureiro, Joseph J., Cambridge, MA, UNITED STATES
Wenland, Jurgen, Bad Harzburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2002048813 A1 20020425
AI US 2001-823240 A1 20010330 (9)
PRAI US 2000-194564P 20000403 (60)
DT Utility
FS APPLICATION
LN.CNT 3345
INCL INCLM: 435/455.000
INCL INCLS: 424/093.210
NCL NCLM: 435/455.000
NCL NCLS: 424/093.210
IC [7]
ICM: A61K048-00
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 50 OF 204 USPATFULL
AN 2002:78224 USPATFULL
TI Individualized anti-cancer antibodies
IN Young, David S. F., Toronto, CANADA
Takahashi, Miyoko, Toronto, CANADA
PI US 2002041877 A1 20020411
AI US 2000-727361 A1 20001129 (9)
RUI Continuation-in-part of Ser. No. US 1999-415278, filed on 8 Oct 1999,
GRANTED, Pat. No. US 6180357
DT Utility
FS APPLICATION
LN.CNT 1220
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:53:01 ON 05 NOV 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
ENTERED AT 10:53:32 ON 05 NOV 2002
9309 S HER2 OR ERB2 OR CERBB2 OR P185
3941 S L1 AND ANTIBOD?
503 S L2 AND CHEMOTHERAPEUTIC?
418 DUP REM L3 (85 DUPLICATES REMOVED)
5 S L4 NOT PY=>1996
3941 S L1 AND ANTIBODY
1252 S L6 AND CHEMO?
1178 S L7 AND CANCER
206 S L8 AND COLORECTAL
204 DUP REM L9 (2 DUPLICATES REMOVED)
0 S L10 NOT PY=> 1996

=> d l5 2 all

L5 ANSWER 2 OF 5 CANCERLIT
AN 95611685 CANCERLIT
DN 95611685
TI Monoclonal antibodies directed against growth factor receptors
enhance the efficacy of chemotherapeutic agents (Meeting
abstract).
AU Basella J; Fan Z; Norton L; Mendelsohn J
CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
SO Ann Oncol, (1994) 5 (Suppl 5) A010.
ISSN: 0923-7534.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology
EM 199509
ED Entered STN: 19950906
AB Last Updated on STN: 19950906
Several lines of evidence suggest that growth factor receptor blockade may
enhance the antitumor effects of chemotherapeutic agents. We
have produced monoclonal antibodies (MAbs) directed against the
epidermal growth factor receptor (EGFR). MAbs 225 (IGG1) and 528 (IgG2a)
are capable of preventing growth of subcutaneous human tumor xenografts in
nude mice when treatment is started shortly after tumor cell inoculation,
but they are only moderately inhibitory after tumors are well developed.
Therefore, we have explored combination treatment with
chemotherapeutic agents plus anti-EGFR MAbs. Three drugs have been
studied: doxorubicin, paclitaxel (Taxol) and cisplatin. Treatment of well
established (greater than 300 mm3) A431 squamous carcinoma xenografts with
maximally tolerated doses of doxorubicin (5 mg/kg ip for two successive
days) had weak antitumor activity, whereas treatment in combination with
either MAbs 528 or 225 at a dose level of 1 mg ip twice a week or higher
resulted in eradication of tumors in 40 to 69% of the animals in several
independently conducted experiments. Similar results were obtained when
the same combination was used in well developed (greater than 200 mm3)
MDA-468 breast adenocarcinoma xenografts. In subsequent studies, well
developed MDA-468 nude mice xenografts were treated with paclitaxel (10-20
mg/kg weight iv x 2) in combination with MAb 528 2 mg intraperitoneally
(ip) twice a week for ten doses. There was striking inhibition of growth
compared with animals treated with either paclitaxel or MAb 528 alone.
Studies with cisplatin in well established A431 cell xenografts at a
maximally tolerated dose of 6 mg/kg x 2 in combination with MAb 225 have
also resulted in eradication of xenografts resistant to drug alone. We
then analyzed the effects of doxorubicin and paclitaxel in combination
with MAb 4D5 directed against the HER2 receptor. BT-474 breast
adenocarcinoma cells, which express high levels of HER2, were
grown to a mean size of 200 mm3. A dose of 4D5 that resulted in a modest
inhibition of growth was chosen for these studies. Treatment with anti-
HER2 MAb 4D5 alone (0.3 mg/kg ip twice a week) produced 35% growth

inhibition, paclitaxel alone (20 mg/kg iv) resulted in 35% inhibition and doxorubicin alone (10 mg/kg ip) in 27% inhibition of growth. The combined treatment with paclitaxel plus 4D5 resulted in a major antitumor activity with 93% inhibition of growth, and doxorubicin plus 4D5 gave 70% inhibition. Studies of cisplatin in combination with 4D5 are underway. In all of the studies, MABs did not increase the toxicity of the chemotherapeutic agents in animals as determined by animal survival and weight loss. Clinical trials that build on these results are planned. In summary, anti-EGFR MABs markedly enhance the antitumor effects of the chemotherapeutic agents doxorubicin, paclitaxel and cisplatin. Anti-HER2 MAB also enhances the antitumor effects of doxorubicin and more significantly of paclitaxel. Studies of mechanisms are underway.

RN 15663-27-1 (Cisplatin); 23214-92-8 (Doxorubicin); 33069-62-4 (Paclitaxel)
CN 0 (Antibodies, Monoclonal); 0 (Receptors, Growth Factor)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.28	100.49

STN INTERNATIONAL LOGOFF AT 11:20:00 ON 05 NOV 2002